<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Guide to low-dose naltrexone (LDN) for chronic pain - emerging treatment with immunomodulatory effects.">
    <meta name="keywords" content="low dose naltrexone, LDN, chronic pain treatment, fibromyalgia LDN, autoimmune LDN">
    <title>Low-Dose Naltrexone | ChronicSoreness</title>
    <link rel="stylesheet" href="../css/styles.css">
</head>
<body>
    <header class="header"><nav class="nav-container"><div class="logo"><a href="../index.html"><span class="logo-icon">ðŸ’œ</span><span class="logo-text"><strong>Chronic</strong>Soreness</span></a></div><button class="mobile-menu-toggle" aria-label="Toggle menu"><span class="hamburger"></span></button><ul class="nav-menu"><li><a href="../conditions.html">Conditions</a></li><li><a href="../treatments.html">Treatments</a></li><li><a href="../medications.html">Medications</a></li><li><a href="../exercise.html">Exercise</a></li><li><a href="../nutrition.html">Nutrition</a></li><li><a href="../mental-health.html">Mental Health</a></li></ul></nav></header>
    <main id="main-content">
        <article class="page-header"><h1>Low-Dose Naltrexone (LDN)</h1><p>An emerging off-label treatment</p></article>
        <section class="content-section">
            <div class="container">
                <h2>What Is Low-Dose Naltrexone?</h2>
                <p>Naltrexone is an opioid antagonist FDA-approved for addiction treatment at 50mg. At much lower doses (1-5mg), it may have immunomodulatory and anti-inflammatory effects. LDN is used off-label for various chronic pain conditions.<sup>1</sup></p>

                <h2>How It May Work<sup>2</sup></h2>
                <ul>
                    <li>Brief opioid receptor blockade</li>
                    <li>Rebound increase in endorphins</li>
                    <li>May reduce microglial activation</li>
                    <li>Anti-inflammatory effects</li>
                    <li>Exact mechanism unclear</li>
                </ul>

                <h2>Conditions Being Studied</h2>
                <ul>
                    <li>Fibromyalgia</li>
                    <li>Chronic pain syndromes</li>
                    <li>Autoimmune conditions (Crohn's, MS)</li>
                    <li>Complex regional pain syndrome</li>
                </ul>

                <h2>Dosing</h2>
                <ul>
                    <li>Usually 1.5-4.5mg at bedtime</li>
                    <li>Start low (0.5-1mg)</li>
                    <li>Increase gradually</li>
                    <li>Compounded from pharmacies</li>
                </ul>

                <h2>Current Evidence<sup>3</sup></h2>
                <ul>
                    <li>Promising but limited studies</li>
                    <li>Best evidence for fibromyalgia</li>
                    <li>Small trials show benefit</li>
                    <li>Larger studies needed</li>
                    <li>Generally well tolerated</li>
                </ul>

                <h2>Side Effects</h2>
                <ul>
                    <li>Vivid dreams (common initially)</li>
                    <li>Sleep disturbance</li>
                    <li>Headache</li>
                    <li>Nausea</li>
                    <li>Usually mild and temporary</li>
                </ul>

                <h2>Important Considerations</h2>
                <ul>
                    <li>Cannot use with opioid medications</li>
                    <li>Not FDA-approved for pain</li>
                    <li>May not be covered by insurance</li>
                    <li>Requires compounding pharmacy</li>
                </ul>

                <h2>References</h2>
                <ol>
                    <li>Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. <em>Clin Rheumatol</em>. 2014;33(4):451-459.</li>
                    <li>Toljan K, Vrooman B. Low-dose naltrexone (LDN) - Review of therapeutic utilization. <em>Med Sci</em>. 2018;6(4):82.</li>
                    <li>Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. <em>Arthritis Rheum</em>. 2013;65(2):529-538.</li>
                </ol>
            </div>
        </section>
    </main>
    <footer class="footer"><div class="container"><p class="disclaimer">The information provided is for educational purposes only and is not medical advice.</p><p class="copyright">Â© 2024 ChronicSoreness. All rights reserved.</p></div></footer>
    <script src="../js/main.js"></script>
</body>
</html>
